Compare Jones Lang LaSalle Inc (JLL) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Organon & Co. Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $294.36 (market cap $13.73B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Jones Lang LaSalle Inc is far larger — about 3.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Organon & Co. Common Stock for 0 Days on average.
| JLL | OGN | |
|---|---|---|
Market Cap | $13.73B | $3.62B |
Volume | 368,437 | 2,892,999 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $13.81 |
52-Week Low | $280.16 | $5.70 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $16.49B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $295.25, down 0.96% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $20.9B in 2022 to $26.1B in 2025, and improving net margins. Recent acquisitions and strategic appointments highlight operational momentum, while analyst consensus remains bullish with a $450.50 price target.
The outlook is positive given valuation discounts (P/E 14.31, P/S 0.52) and robust cash flow growth, though risks include real estate market cyclicality and technical resistance near $297. Upside hinges on continued execution and sector tailwinds, supporting a constructive view for long-term investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
